Global Leader in Myopia Treatment Demonstrates Long-Term Benefits of MiSight® 1 Day
Kuala Lumpur, Malaysia, July 15, 2024 /PRNewswire/ — Cooper VisionAs a Gold Sponsor, the world leader in myopia treatment, FiveNumber World Congress of Paediatric Ophthalmology and Strabismus (WCPOS V) in Kuala Lumpur, MalaysiaEvent period July 11th to 13thThe event highlighted CooperVision’s commitment to improving pediatric eye health. Asia Its pioneering role in myopia control was highlighted. WCPOS V, organized by the World Society of Paediatric Ophthalmology and Strabismus, brought together more than 1,200 paediatric ophthalmologists, researchers and industry leaders from around the world, highlighting its significant impact and reach.
As the prevalence and severity of pediatric myopia increases, CooperVision is committed to making a lasting impact on the future of pediatric ophthalmology through leading research and groundbreaking solutions. Attended by leading ophthalmologists from around the world, the event provided a platform for CooperVision to network with experts and explore innovative solutions.
A highlight for CooperVision at WCPOS V was the presentation of results from the seven-year MiSight® 1 day clinical trial, the world’s longest continuous soft contact lens clinical trial for myopia control. The presented clinical evidence supports the reliability and effectiveness of MiSight® 1 day, the world’s first FDA-approved soft contact lens designed to slow the progression of myopia in children aged 8-12 years at the start of treatment. These insights were highlighted during a lunch symposium held at the same venue. Additionally, results from a separate investigator-initiated study showed no adverse effects on corneal health in participants in the MiSight® 1 day clinical trial after 10 years of full-time wear, further supporting the safety of long-term soft contact lens wear.
Findings from another investigator-led study: Nicola LoganHe was the principal investigator of MiSight® 1-Day Clinical Trial Aston University’s MiSight® 1 day has demonstrated the long-term safety of the lens, reinforcing its role as a cornerstone of myopia management. “The seven-year clinical trial of MiSight® 1 day is the longest running soft contact lens study in children and has given researchers, academics and the wider eye care professional community confidence in its ability to significantly slow the progression of myopia in children,” said the Professor. Nicola Logan“Furthermore, after 10 years of constant wear, corneal health was unaffected, further supporting the role of MiSight 1 day as a clinically useful intervention to address pediatric myopia.”
upon July 13CooperVision presented key research findings at Poster Village 12 at WCPOS V. Kuala Lumpur, Malaysia. Elizabeth LamMs. , Director of Myopia Management, Global Professional Affairs at CooperVision, presented on the 6-year cumulative treatment effect of MiSight® 1 day. Her presentation demonstrated that an alternative approach to estimating efficacy allows the cumulative treatment effect of MiSight® 1 day to be evaluated over multiple years beyond Part 1 of the MiSight® 1 day clinical trial. Additionally, Katie HarropCooperVision’s Senior Manager of Global Professional Education presented the results of a study evaluating the safety and ocular health of Paragon CRT® orthokeratology lenses in Chinese patients.
More than 85 scientific sessions, panel discussions and workshops covering a wide range of topics related to pediatric ophthalmology and strabismus were held at WCPOS V. Key themes included advances in myopia management, innovative surgical techniques for pediatric eye diseases and strategies to improve global disparities in pediatric eye health.
“Our participation in WCPOS V reflects our commitment to tackling the myopia epidemic. Asia through early intervention and evidence-based treatments.” Shilla GuptaGeneral Manager, Myopia Management, Asia Pacific, CooperVision. “We are committed to equipping pediatric ophthalmologists and eye care professionals with the knowledge and tools they need to make a significant impact on children’s vision health.”
For more information about CooperVision and its commitment to pediatric eye care, please visit Cooper Vision.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading contact lens manufacturers. The company produces a wide range of daily, biweekly and monthly disposable soft contact lenses featuring advanced materials and optical technologies, as well as premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the most challenging vision problems, including astigmatism, presbyopia, pediatric myopia and highly irregular corneas, and offers the most comprehensive selection of spherical, toric and multifocal products. The combination of innovative products and focused physician support allows the company to bring a fresh perspective to the market, delivering real benefits to customers and wearers. For more information, please visit www.coopervision.com.
About Cooper Companies
Cooper Companies (Nasdaq: COO) is a leading global medical device company focused on improving the life of every person. The company operates through two segments: CooperVision and Cooper Surgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. Cooper Surgical is a leading fertility and women’s health company with a mission to support women, babies and families during their most critical medical moments. The company is headquartered in San Diego, California, USA. San Ramon, CaliforniaCooperCompanies has more than 15,000 employees and sells products in more than 130 countries. For more information, visit www.coopercos.com.
SA11807_1
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/coopervision-champions-childrens-eye-health-at-wcpos-v-2024-302196600.html
Source: CooperVision
